Jefferies analyst Akash Tewari upgraded BioNTech SE (BNTX – Research Report) to a Buy today and set a price target of $150.00. The ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The ...

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

The upgrade was driven by the potential of BioNTech's investigational drug BNT327, which could significantly impact the company's revenue. The analyst noted that despite molecular differences ...

Prior concerns about BioNTech centered on the absence of sufficient randomized data to support the company's transition towards its oncology pipeline. The analyst noted that despite the trials for ...

The upgrade was driven by the potential of BioNTech's investigational drug BNT327, which could significantly impact the company's revenue. The analyst noted that despite molecular differences, BNT327 ...

Prior concerns about BioNTech centered on the absence of sufficient randomized data to support the company's transition towards its oncology pipeline. The analyst noted that despite the trials for ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Stay updated on the latest analyst actions and market trends with this financial article covering upgrades and downgrades for ...